Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.43 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.39 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.39 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.39 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8071396 | 0.92 | TAAR1 (0.52) | TAAR1HTR2ASIRT2HMOX1CYP2A6 | |
| SCHEMBL3745225 | 0.90 | TAAR1 (0.50) | TAAR1HTR2ASIRT2HMOX1 | |
| SCHEMBL8071279 | 0.90 | TAAR1 (0.50) | TAAR1HTR2ASIRT2HMOX1 | |
| SCHEMBL8070958 | 0.90 | TAAR1 (0.50) | TAAR1HTR2ASIRT2HMOX1 | |
| SCHEMBL5795842 | 0.90 | TAAR1 (0.50) | TAAR1HTR2ASIRT2HMOX1 | |
| SCHEMBL8062227 | 0.90 | TAAR1 (0.50) | TAAR1HTR2ASIRT2HMOX1 | |
| SCHEMBL8072828 | 0.90 | TAAR1 (0.50) | TAAR1HTR2ASIRT2HMOX1 | |
| SCHEMBL9671990 | 0.89 | TDP1 (0.48) | TAAR1HTR2ASIGMAR1TDP1 | |
| SCHEMBL5238701 | 0.86 | TAAR1 (0.62) | TAAR1HTR2AHMOX1CYP2A6IDO1 | |
| SCHEMBL7904900 | 0.86 | TAAR1 (0.62) | TAAR1HTR2AHMOX1CYP2A6IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| EP-4577526-A1 | VHH ANTIBODY CONJUGATES | Abdera Therapeutics Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| CN-120051461-A | VHH antibody conjugates | 雅博得乐医疗公司 | 2025-05-27 | — | — | CN | disclosed |
| US-12257247-B2 | Targeted degradation of VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-03-25 | — | — | US | disclosed |
| US-20240285604-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-29 | — | — | US | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024044549-A1 | VHH ANTIBODY CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044549-A1 | VHH ANTIBODY CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-5919793-A | QUINUCLIDINE DERIVATIVES, SQUALENE SYNTHETASE INHIBITORS, ANTICHOLESTEROL AGENTS | ZENECA LIMITED (GB) | 1999-07-06 | — | — | US | disclosed |
| US-5637736-A | Process for preparing 1-bromoalkylbenzene derivatives and intermediates thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-06-10 | — | — | US | disclosed |
| EP-0696284-A1 | HETEROCYCLIC DERIVATIVES | ZENECA LIMITED (GB) | 1996-02-14 | — | — | EP | disclosed |
| EP-0637580-A1 | Process for preparing 1-bromoalkylbenzene derivatives and intermediates thereof | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1995-02-08 | — | — | EP | disclosed |
| WO-1994025459-A1 | HETEROCYCLIC DERIVATIVES | ZENECA LIMITED (GB) | 1994-11-10 | — | — | WO | disclosed |
| US-5175157-A | Cardiovascular disorders | BOEHRINGER INGELHEIM GMBH (DE) | 1992-12-29 | — | — | US | disclosed |
| EP-0259782-B1 | NAPHTHALENE AND INDANE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESSES FOR THEIR PREPARATION | Dr. Karl Thomae GmbH (DE) | 1990-12-27 | — | — | EP | disclosed |
| EP-0224794-B1 | CYCLIC AMINE DERIVATIVES, MEDICINES CONTAINING THESE COMPOUNDS AND PROCESS FOR THEIR PREPARATION | Dr. Karl Thomae GmbH (DE) | 1990-09-12 | — | — | EP | disclosed |
| EP-0332064-A2 | Benzocycloheptene derivatives, pharmaceutical preparations containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1989-09-13 | — | — | EP | disclosed |
| EP-0224794-A2 | Cyclic amine derivatives, medicines containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1987-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285604-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | TAAR1 3001/4885HTR2A 4338/4885SIRT2 4299/4885 |
| US-12257247-B2 | Targeted degradation of VAV1 | VAV1, KRAS, CBL | TAAR1 3001/4885HTR2A 4338/4885SIRT2 4299/4885 |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | TAAR1 3001/4885HTR2A 4338/4885SIRT2 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.